MUC1 is a heterodimeric transmembrane glycoprotein formed by two subunits(N terminal and C terminal). MUC1 is aber-rantly overexpressed in the epithelium originated tumor and is closely related to tumor development. MUC1-N interacts with ICAM-1,E-selectin and Galectin-3 and mediates signal transduction through MUC1-C;MUC1-C interacts with ErbB and other receptor tyro-sine kinases and engages in the PI3K→AKT,MAP,NF-κB,Wnt,STAT,P53 and Erα pathways,resulting in tumor proliferation,inva-sion and migration and chemoresistance. We review the role of MUC1-N and MUC1-C in interacting with other molecules and acti-vating signaling pathways. Finally,we review the clinical trials of the therapies of MUC1-N monoclonal antibodies,MUC1-C small molecule peptides and MUC1 vaccines.